{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:39:02Z","timestamp":1790721542096,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"},{"DOI":"10.13039\/501100008131","name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12325-022-02193-3","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T12:03:49Z","timestamp":1654776229000},"page":"3425-3448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Robert P.","family":"Finger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Quen\u00e9chdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Karcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Souied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"issue":"4","key":"2193_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina. 2017;1(4):314\u201321. https:\/\/doi.org\/10.1016\/j.oret.2016.12.004.","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"2193_CR2","doi-asserted-by":"publisher","first-page":"1508.e1","DOI":"10.1016\/j.ophtha.2006.02.064","volume":"113","author":"U Chakravarthy","year":"2006","unstructured":"Chakravarthy U, Adamis AP, Cunningham ET, et al. Year\u00a02 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113(9):1508.e1-25. https:\/\/doi.org\/10.1016\/j.ophtha.2006.02.064.","journal-title":"Ophthalmology"},{"key":"2193_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2018.03.007","volume":"190","author":"S Sepahi","year":"2018","unstructured":"Sepahi S, Mohajeri SA, Hosseini SM, et al. Effects of crocin on diabetic maculopathy: a placebo-controlled randomized clinical trial. Am J Ophthalmol. 2018;190:89\u201398. https:\/\/doi.org\/10.1016\/j.ajo.2018.03.007.","journal-title":"Am J Ophthalmol"},{"key":"2193_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/bmb\/ldn012","volume":"85","author":"HL Cook","year":"2008","unstructured":"Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull. 2008;85:127\u201349. https:\/\/doi.org\/10.1093\/bmb\/ldn012.","journal-title":"Br Med Bull."},{"issue":"3","key":"2193_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/tvst.4.3.6","volume":"4","author":"I Mantel","year":"2015","unstructured":"Mantel I. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl Vis Sci Technol. 2015;4(3):6. https:\/\/doi.org\/10.1167\/tvst.4.3.6.","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"2193_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","volume":"30","author":"V Chong","year":"2016","unstructured":"Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond). 2016;30(2):270\u201386. https:\/\/doi.org\/10.1038\/eye.2015.217.","journal-title":"Eye (Lond)"},{"issue":"4","key":"2193_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00417-013-2562-6","volume":"252","author":"A Wolf","year":"2014","unstructured":"Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):647\u201355. https:\/\/doi.org\/10.1007\/s00417-013-2562-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2193_CR8","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1038\/s41598-022-06362-w","volume":"12","author":"F Ziemssen","year":"2022","unstructured":"Ziemssen F, Agostini H, Feltgen N, et al. A model to quantify the influence of treatment patterns and optimize outcomes in nAMD. Sci Rep. 2022;12(1):2789. https:\/\/doi.org\/10.1038\/s41598-022-06362-w.","journal-title":"Sci Rep"},{"issue":"2","key":"2193_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","volume":"244","author":"R Tadayoni","year":"2021","unstructured":"Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2021;244(2):93\u2013101. https:\/\/doi.org\/10.1159\/000513048.","journal-title":"Ophthalmologica"},{"issue":"1","key":"2193_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017.","journal-title":"Ophthalmology"},{"key":"2193_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05518-0","author":"R Khoramnia","year":"2021","unstructured":"Khoramnia R, Figueroa MS, Hattenbach LO, et al. Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefes Arch Clin Exp Ophthalmol. 2021. https:\/\/doi.org\/10.1007\/s00417-021-05518-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2193_CR12","unstructured":"European Medicines Agency, Committee for medicinal products for human use (CHMP), 2021. Draft agenda for the meeting on 21\u201324 June 2021. [Online] Available at: https:\/\/www.ema.europa.eu\/en\/documents\/agenda\/agenda-chmpagenda-21-24-june-2021-meeting_en.pdf. Accessed Jan 2022."},{"key":"2193_CR13","unstructured":"National Institute for Health and Care Excellence (NICE), 2021. Health Technology Appraisal, Faricimab for wet age-related macular degeneration, Draft Scope [Online] Available at: https:\/\/www.nice.org.uk\/guidance\/gid-ta10799\/documents\/draftscope-post-referral. Accessed Jan 2022."},{"key":"2193_CR14","unstructured":"VABYSMOTM (faricimab-svoa) injection, for intravitreal use. Accessed Feb 24, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761235s000lbl.pdf."},{"key":"2193_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"7414","key":"2193_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"2193_CR17","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials. National Institute for Health and Care Excellence (NICE); 2014. Accessed Nov 11, 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310372\/"},{"key":"2193_CR18","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE); 2014. Accessed Nov 11, 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/"},{"issue":"5","key":"2193_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jval.2014.06.001","volume":"17","author":"A Laws","year":"2014","unstructured":"Laws A, Kendall R, Hawkins N. A comparison of national guidelines for network meta-analysis. Value Health. 2014;17(5):642\u201354. https:\/\/doi.org\/10.1016\/j.jval.2014.06.001.","journal-title":"Value Health"},{"issue":"2","key":"2193_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12.","journal-title":"Res Synth Methods"},{"key":"2193_CR21","unstructured":"National Institute for Health and Care Excellence (NICE), 2018. Macular degeneration, Appendix G: Network meta-analysis. [Online] Available at: https:\/\/www.nice.org.uk\/guidance\/ng82\/evidence\/appendix-gnetwork-metaanalysis-pdf-4723229204. Accessed Dec 2021."},{"key":"2193_CR22","doi-asserted-by":"publisher","first-page":"204062232095334","DOI":"10.1177\/2040622320953349","volume":"11","author":"L Ye","year":"2020","unstructured":"Ye L, Jiaqi Z, Jianchao W, Zhaohui F, Liang Y, Xiaohui Z. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis. Ther Adv Chronic Dis. 2020;11:2040622320953349. https:\/\/doi.org\/10.1177\/2040622320953349.","journal-title":"Ther Adv Chronic Dis"},{"key":"2193_CR23","doi-asserted-by":"publisher","first-page":"CD005139","DOI":"10.1002\/14651858.CD005139.pub4","volume":"3","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3:CD005139. https:\/\/doi.org\/10.1002\/14651858.CD005139.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2193_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89\u201399. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.028.","journal-title":"Ophthalmology"},{"issue":"10","key":"2193_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"RN Evans","year":"2020","unstructured":"Evans RN, Reeves BC, Maguire MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol. 2020;138(10):1043\u201351. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3001.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2193_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125(1):57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.014.","journal-title":"Ophthalmology"},{"issue":"6","key":"2193_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","volume":"126","author":"PJ Kertes","year":"2019","unstructured":"Kertes PJ, Galic IJ, Greve M, et al. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology. 2019;126(6):841\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2019.01.013.","journal-title":"Ophthalmology"},{"issue":"7","key":"2193_CR28","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1111\/aos.14756","volume":"99","author":"XY Zhao","year":"2021","unstructured":"Zhao XY, Meng LH, Liu SZ, Chen YX. Efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials. Acta Ophthalmol. 2021;99(7):e1041\u201350. https:\/\/doi.org\/10.1111\/aos.14756.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"2193_CR29","doi-asserted-by":"publisher","first-page":"E1522","DOI":"10.3390\/jcm9051522","volume":"9","author":"AA Plyukhova","year":"2020","unstructured":"Plyukhova AA, Budzinskaya MV, Starostin KM, et al. Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies. J Clin Med. 2020;9(5):E1522. https:\/\/doi.org\/10.3390\/jcm9051522.","journal-title":"J Clin Med"},{"issue":"1","key":"2193_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2017-000109","volume":"4","author":"M Weber","year":"2019","unstructured":"Weber M, Velasque L, Coscas F, Faure C, Aubry I, Cohen SY. Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study. BMJ Open Ophthalmol. 2019;4(1): e000109. https:\/\/doi.org\/10.1136\/bmjophth-2017-000109.","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"2193_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40123-021-00350-5","volume":"10","author":"J Carrasco","year":"2021","unstructured":"Carrasco J, Daien V, Eldem BM, Spoorendonk JA, Yoon J. 2-year real-world outcomes with intravitreal aflibercept in neovascular age-related macular degeneration: literature review and meta-analysis of patient-relevant outcomes. Ophthalmol Ther. 2021;10(3):397\u2013411. https:\/\/doi.org\/10.1007\/s40123-021-00350-5.","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"2193_CR32","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","volume":"40","author":"FG Holz","year":"2020","unstructured":"Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study. Retina Phila PA. 2020;40(9):1673\u201385. https:\/\/doi.org\/10.1097\/IAE.0000000000002670.","journal-title":"Retina Phila PA"},{"key":"2193_CR33","unstructured":"Novartis, 2020. Beovu [U.S. Prescribing Information]. [Online] Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761125s004lbl.pdf. Accessed Dec 2021."},{"issue":"7","key":"2193_CR34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011.","journal-title":"Ophthalmology"},{"key":"2193_CR35","doi-asserted-by":"publisher","unstructured":"Singer M, Albini TA, Seres A, et al. Clinical Characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER. Ophthalmol Retina. 2021:S2468-6530(21)00162-7. https:\/\/doi.org\/10.1016\/j.oret.2021.05.003.","DOI":"10.1016\/j.oret.2021.05.003"},{"issue":"6","key":"2193_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","volume":"5","author":"CR Baumal","year":"2021","unstructured":"Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5(6):519\u201327. https:\/\/doi.org\/10.1016\/j.oret.2020.09.020.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"2193_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00347-021-01321-8","volume":"118","author":"FG Holz","year":"2021","unstructured":"Holz FG, Heinz C, Wolf A, Hoerauf H, Pleyer U. Intraocular inflammation with brolucizumab use: patient management-diagnosis-therapy. Ophthalmologe. 2021;118(3):248\u201356. https:\/\/doi.org\/10.1007\/s00347-021-01321-8.","journal-title":"Ophthalmologe"},{"issue":"6","key":"2193_CR38","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41433-020-01324-w","volume":"35","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, et al. Brolucizumab-foreseeable workflow in the current scenario. Eye (Lond). 2021;35(6):1548\u201350. https:\/\/doi.org\/10.1038\/s41433-020-01324-w.","journal-title":"Eye (Lond)"},{"key":"2193_CR39","unstructured":"Novartis, 2022. Beovu [Global use and safety information for Healthcare Professionals]. [Online] Available at: https:\/\/www.brolucizumab.info\/. Accessed Apr 2022."},{"key":"2193_CR40","unstructured":"National Institute for Health and Care Excellence, 2014. Network meta-analyses \u2013 methods and detailed results. [Online] Available at: https:\/\/www.nice.org.uk\/guidance\/cg184\/evidence\/appendix-enetwork-metaanalyses-methods-and-detailed-results-pdf-193203763. Accessed Dec 2021."},{"key":"2193_CR41","unstructured":"NICE Guide to the methods of technology appraisal. Published online 2013. http:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02193-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02193-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02193-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T18:12:30Z","timestamp":1658686350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02193-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2193"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02193-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"29 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}